-
1
-
-
57749193512
-
-
19093700 10.2165/0003495-200868180-00004 1:CAS:528:DC%2BD1MXislKhsb4%3D
-
Glare PA, Danwoodie D. Drugs. 2008;68(18):2575-90.
-
(2008)
Drugs
, vol.68
, Issue.18
, pp. 2575-2590
-
-
Glare, P.A.1
Danwoodie, D.2
-
2
-
-
38449089186
-
-
18097455 10.1038/ncponc1021 1:CAS:528:DC%2BD1cXhtFGntA%3D%3D
-
Herrstedt J. Nat Clin Pract Oncol. 2008;5(1):32-43.
-
(2008)
Nat Clin Pract Oncol
, vol.5
, Issue.1
, pp. 32-43
-
-
Herrstedt, J.1
-
3
-
-
0030782224
-
ABC of palliative care. Nausea, vomiting, and intestinal obstruction
-
9374893 10.1136/bmj.315.7116.1148 1:STN:280:DyaK1c%2Fkt1ejtA%3D%3D
-
Baines MJ. ABC of palliative care. Nausea, vomiting, and intestinal obstruction. BMJ. 1997;315(7116):1148-50.
-
(1997)
BMJ
, vol.315
, Issue.7116
, pp. 1148-1150
-
-
Baines, M.J.1
-
4
-
-
0036937249
-
Palliation of nausea and vomiting
-
Mannix KA. Palliation of nausea and vomiting. CME Can Med. 2002;1(1):18-22.
-
(2002)
CME Can Med
, vol.1
, Issue.1
, pp. 18-22
-
-
Mannix, K.A.1
-
5
-
-
0027366610
-
Control of chemotherapy-induced emesis
-
Grunberg SM, Hesketh PJ. Control of chemotherapy-induced emesis. N Engl J Med 329:1790-96.
-
N Engl J Med
, vol.329
, pp. 1790-1796
-
-
Grunberg, S.M.1
Hesketh, P.J.2
-
6
-
-
0029811856
-
-
8692546 10.1159/000227636
-
Cubeddu LX. Oncology. 1996;53 Suppl 1:18-25.
-
(1996)
Oncology
, vol.53
, Issue.SUPPL. 1
, pp. 18-25
-
-
Cubeddu, L.X.1
-
7
-
-
0032951327
-
Randomized phase II study of the neurokinin 1 receptor antagonist CJ-11,974 in the control of cisplatin-induced emesis
-
10458252 1:CAS:528:DyaK1MXltVyrtA%3D%3D
-
Hesketh PJ, Gralla RJ, Webb RT, Ueno W, DelPrete S, Bachinsky ME, et al. Randomized phase II study of the neurokinin 1 receptor antagonist CJ-11,974 in the control of cisplatin-induced emesis. J Clin Oncol. 1999;17:338-43.
-
(1999)
J Clin Oncol
, vol.17
, pp. 338-343
-
-
Hesketh, P.J.1
Gralla, R.J.2
Webb, R.T.3
Ueno, W.4
Delprete, S.5
Bachinsky, M.E.6
-
8
-
-
0034742680
-
Potential role of the NK1 receptor antagonists in chemotherapy-induced nausea and vomiting
-
11497388 10.1007/s005200000199 1:STN:280:DC%2BD3MvltFCqtw%3D%3D
-
Hesketh PJ. Potential role of the NK1 receptor antagonists in chemotherapy-induced nausea and vomiting. Support Care Cancer. 2001;9(5):350-4.
-
(2001)
Support Care Cancer
, vol.9
, Issue.5
, pp. 350-354
-
-
Hesketh, P.J.1
-
9
-
-
0036685084
-
Progress in preventing chemotherapy-induced nausea and vomiting
-
12184469 10.3949/ccjm.69.8.609
-
Markman M. Progress in preventing chemotherapy-induced nausea and vomiting. Cleve Clin J Med. 2002;69(8):609-17.
-
(2002)
Cleve Clin J Med
, vol.69
, Issue.8
, pp. 609-617
-
-
Markman, M.1
-
10
-
-
33846088469
-
Comparative activity of antiemetic drugs
-
17208005 10.1016/j.critrevonc.2006.08.003
-
Jordan K, Schmoll HJ, Aapro MS. Comparative activity of antiemetic drugs. Crit Rev Oncol Hematol. 2007;61:162-75.
-
(2007)
Crit Rev Oncol Hematol
, vol.61
, pp. 162-175
-
-
Jordan, K.1
Schmoll, H.J.2
Aapro, M.S.3
-
12
-
-
59849112624
-
-
10.1556/MOnkol.52.2008.4.9
-
Toth J, Szanto J. Magy Oncol. 2008;52(4):391-4.
-
(2008)
Magy Oncol
, vol.52
, Issue.4
, pp. 391-394
-
-
Toth, J.1
Szanto, J.2
-
14
-
-
29844438029
-
Prevention of chemotherapy- and radiotherapy induced emesis: Results of the 2004 Perugia International Antiemetic Consensus Conference
-
16314401 10.1093/annonc/mdj936 1:STN:280:DC%2BD28%2FkvVKmtQ%3D%3D
-
Roila F, Hesketh PJ, Herrstedt J. Prevention of chemotherapy- and radiotherapy induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol. 2006;17:20-8.
-
(2006)
Ann Oncol
, vol.17
, pp. 20-28
-
-
Roila, F.1
Hesketh, P.J.2
Herrstedt, J.3
-
15
-
-
80755126820
-
Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
-
21947834 10.1200/JCO.2010.34.4614
-
Basch E, Prestrud AA, Hesketh PJ. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2011;29(31):4189-98.
-
(2011)
J Clin Oncol
, vol.29
, Issue.31
, pp. 4189-4198
-
-
Basch, E.1
Prestrud, A.A.2
Hesketh, P.J.3
-
16
-
-
44849134443
-
Chemotherapy-induced nausea and vomiting
-
18525044 10.1056/NEJMra0706547 1:CAS:528:DC%2BD1cXmvFKltL0%3D
-
Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med. 2008;358:2482-94.
-
(2008)
N Engl J Med
, vol.358
, pp. 2482-2494
-
-
Hesketh, P.J.1
-
17
-
-
0037561044
-
-
10.1038/sj.bjc.6601033 1:CAS:528:DC%2BD3sXksVKjur0%3D
-
Dewit R. Br J Cancer. 2003;88(12):1823-7.
-
(2003)
Br J Cancer
, vol.88
, Issue.12
, pp. 1823-1827
-
-
Dewit, R.1
-
18
-
-
14544288652
-
Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications
-
15718327 10.1200/JCO.2005.04.022 1:CAS:528:DC%2BD2MXitl2gurc%3D
-
Geling O, Eichler H. Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol. 2005;23:1289-94.
-
(2005)
J Clin Oncol
, vol.23
, pp. 1289-1294
-
-
Geling, O.1
Eichler, H.2
-
19
-
-
0034666393
-
Oral serotonin type 3-receptor antagonists for prevention of chemotherapy-induced emesis
-
Lindley C, Blower P. Oral serotonin type 3-receptor antagonists for prevention of chemotherapy-induced emesis. Am J Health-Syst Pharm 57 (18): 1685-97.
-
Am J Health-Syst Pharm
, vol.57
, Issue.18
, pp. 1685-1697
-
-
Lindley, C.1
Blower, P.2
-
20
-
-
34250810912
-
-
17587360 10.1111/j.1365-2354.2006.00760.x 1:STN:280: DC%2BD2szntFyhtw%3D%3D
-
Kast RE. European Journal of Cancer Care. 2007;16:351-4.
-
(2007)
European Journal of Cancer Care
, vol.16
, pp. 351-354
-
-
Kast, R.E.1
-
21
-
-
0029898199
-
Single-blind study of the effects of intravenous dolasetron mesylate versus ondansetron on electrocardiographic parameters in normal volunteers
-
8797136 10.1097/00005344-199607000-00009 1:CAS:528:DyaK28XjvVahs70%3D
-
Benedict CR, Arbogast R, Martin L, et al. Single-blind study of the effects of intravenous dolasetron mesylate versus ondansetron on electrocardiographic parameters in normal volunteers. J Cardiovasc Pharmacol. 1996;28:53-9.
-
(1996)
J Cardiovasc Pharmacol
, vol.28
, pp. 53-59
-
-
Benedict, C.R.1
Arbogast, R.2
Martin, L.3
-
22
-
-
1242321114
-
-
14973304 10.1177/0091270003262950 1:CAS:528:DC%2BD2cXisFGlsLc%3D
-
Shadle CR. J Clin Pharmacol. 2004;44:215-23.
-
(2004)
J Clin Pharmacol
, vol.44
, pp. 215-223
-
-
Shadle, C.R.1
-
23
-
-
27644482810
-
Effect of aprepitant on the pharmacokinetics and pharmacodynamics of warfarin
-
15983826 10.1007/s00228-005-0907-8 1:CAS:528:DC%2BD2MXmsFWlsLo%3D
-
Depre M, Van Hecken A, Oeyen M, et al. Effect of aprepitant on the pharmacokinetics and pharmacodynamics of warfarin. Eur J Clin Pharmacol. 2005;61:341-6.
-
(2005)
Eur J Clin Pharmacol
, vol.61
, pp. 341-346
-
-
Depre, M.1
Van Hecken, A.2
Oeyen, M.3
-
24
-
-
0031936052
-
Dopamine: Pharmacologic and therapeutic aspects
-
10099036 10.1097/00045391-199801000-00007 1:STN:280: DC%2BD3c%2FptFantw%3D%3D
-
Velasco M, Luchsinger A. Dopamine: pharmacologic and therapeutic aspects. Am J Ther. 1998;5(1):37-43.
-
(1998)
Am J Ther
, vol.5
, Issue.1
, pp. 37-43
-
-
Velasco, M.1
Luchsinger, A.2
-
25
-
-
0021879894
-
Lorazepam in cancer patients treated with cisplatin: A drug having antiemetic, amnesic and anxiolytic effects
-
4040158 1:STN:280:DyaL2M3js1CntA%3D%3D
-
Laszlo J, Clark RA, Hanson DC, et al. Lorazepam in cancer patients treated with cisplatin: a drug having antiemetic, amnesic and anxiolytic effects. J Clin Oncol. 1985;3:864-9.
-
(1985)
J Clin Oncol
, vol.3
, pp. 864-869
-
-
Laszlo, J.1
Clark, R.A.2
Hanson, D.C.3
-
26
-
-
0035822323
-
Cannabinoids for control of chemotherapy induced nausea and vomiting: Quantitative systematic review
-
11440936 10.1136/bmj.323.7303.16
-
Tramèr MR, Carroll D, Campbell FA, et al. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ. 2001;323:16-21.
-
(2001)
BMJ
, vol.323
, pp. 16-21
-
-
Tramèr, M.R.1
Carroll, D.2
Campbell, F.A.3
-
27
-
-
0026443746
-
Phase III double-blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple-day cisplatin-based chemotherapy
-
1423181 10.1002/1097-0142(19921115)70:10<2524: AID- CNCR2820701022>3.0.CO;2-Z
-
Sledge Jr GW, Einhorn L, Nagy C, et al. Phase III double-blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple-day cisplatin-based chemotherapy. Cancer. 1992;70(10):2524-8.
-
(1992)
Cancer
, vol.70
, Issue.10
, pp. 2524-2528
-
-
Sledge, Jr.G.W.1
Einhorn, L.2
Nagy, C.3
-
28
-
-
0031594743
-
5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy
-
9506240 10.2165/00003495-199855020-00002 1:CAS:528:DyaK1cXhs1Sjsrw%3D
-
Gregory RE, Ettinger DS. 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy. Drugs. 1998;55(2):173-89.
-
(1998)
Drugs
, vol.55
, Issue.2
, pp. 173-189
-
-
Gregory, R.E.1
Ettinger, D.S.2
-
29
-
-
17144434135
-
Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy
-
9256141 1:CAS:528:DyaK2sXls1Smu74%3D
-
Lofters WS, Pater JL, Zee B, et al. Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy. J Clin Oncol. 1997;15(8):2966-73.
-
(1997)
J Clin Oncol
, vol.15
, Issue.8
, pp. 2966-2973
-
-
Lofters, W.S.1
Pater, J.L.2
Zee, B.3
-
30
-
-
0029081191
-
Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting
-
8625142 10.1002/1097-0142(19950801)76:3<535: AID-CNCR2820760331>3. 0.CO;2-K 1:STN:280:DyaK283itlSltw%3D%3D
-
Fedele P, Spina M, Valentini M, et al. Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Cancer. 1995;76(3):535-6.
-
(1995)
Cancer
, vol.76
, Issue.3
, pp. 535-536
-
-
Fedele, P.1
Spina, M.2
Valentini, M.3
-
31
-
-
0035988484
-
Clinical evaluation of Ramosetron injections in the treatment of cisplatin-induced nausea and vomiting
-
12166337 1:CAS:528:DC%2BD38XlvFGktrc%3D
-
Noda K, Ikeda M, Yoshida O. Clinical evaluation of Ramosetron injections in the treatment of cisplatin-induced nausea and vomiting. J Int Med Res. 2002;30(3):211-9.
-
(2002)
J Int Med Res
, vol.30
, Issue.3
, pp. 211-219
-
-
Noda, K.1
Ikeda, M.2
Yoshida, O.3
-
32
-
-
33244466064
-
Phase II trial of ramosetron plus dexamethasone in the prevention of cisplatin-induced nausea and vomiting
-
16518975
-
Voravud N, Sriuranpong V. Phase II trial of ramosetron plus dexamethasone in the prevention of cisplatin-induced nausea and vomiting. J Med Assoc Thai. 2005;88(12):1790-6.
-
(2005)
J Med Assoc Thai
, vol.88
, Issue.12
, pp. 1790-1796
-
-
Voravud, N.1
Sriuranpong, V.2
-
33
-
-
0346753572
-
A double-blind, crossover, randomized comparison of granisetron and ramosetron for the prevention of acute and delayed cisplatin-induced emesis in patients with gastrointestinal cancer: Is patient preference a better primary endpoint?
-
14671433 10.1159/000074533 1:CAS:528:DC%2BD3sXps1ygt7w%3D
-
Koizumi W, Tanabe S, Nagaba S, et al. A double-blind, crossover, randomized comparison of granisetron and ramosetron for the prevention of acute and delayed cisplatin-induced emesis in patients with gastrointestinal cancer: is patient preference a better primary endpoint? Chemotherapy. 2003;49(6):316-23.
-
(2003)
Chemotherapy
, vol.49
, Issue.6
, pp. 316-323
-
-
Koizumi, W.1
Tanabe, S.2
Nagaba, S.3
-
34
-
-
33748749890
-
A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in reventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy
-
16766588 10.1093/annonc/mdl137 1:STN:280:DC%2BD28rktVensw%3D%3D
-
Aapro MS, Grunberg SM, Manikhas GM, et al. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in reventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol. 2006;17(9):1441-9.
-
(2006)
Ann Oncol
, vol.17
, Issue.9
, pp. 1441-1449
-
-
Aapro, M.S.1
Grunberg, S.M.2
Manikhas, G.M.3
-
35
-
-
10744219621
-
Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: Results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron
-
14504060 10.1093/annonc/mdg417 1:STN:280:DC%2BD3svktlKitQ%3D%3D
-
Gralla R, Lichinitser M, Van Der Vegt S, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol. 2003;14(10):1570-7.
-
(2003)
Ann Oncol
, vol.14
, Issue.10
, pp. 1570-1577
-
-
Gralla, R.1
Lichinitser, M.2
Van Der Vegt, S.3
-
36
-
-
0344412945
-
Palonosetron Study Group Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: Results of a phase III, single-dose trial versus dolasetron
-
14635083 10.1002/cncr.11817 1:CAS:528:DC%2BD3sXpvFOrt70%3D
-
Eisenberg P, Figueroa-Vadillo J, Zamora R, et al. Palonosetron Study Group Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer. 2003;98(11):2473-82.
-
(2003)
Cancer
, vol.98
, Issue.11
, pp. 2473-2482
-
-
Eisenberg, P.1
Figueroa-Vadillo, J.2
Zamora, R.3
-
37
-
-
0025888322
-
Does dexamethasone enhance control of acute cisplatin induced emesis by ondansetron?
-
1837743 10.1136/bmj.303.6815.1423 1:STN:280:DyaK387islajsg%3D%3D
-
Smyth JF, Coleman RE, Nicolson M, et al. Does dexamethasone enhance control of acute cisplatin induced emesis by ondansetron? BMJ. 1991;303(6815):1423-6.
-
(1991)
BMJ
, vol.303
, Issue.6815
, pp. 1423-1426
-
-
Smyth, J.F.1
Coleman, R.E.2
Nicolson, M.3
-
38
-
-
33847262912
-
Antiemetic activity of corticosteroids in patients receiving cancer chemotherapy: Dosing, efficacy, and tolerability analysis
-
17108149 10.1093/annonc/mdl347 1:STN:280:DC%2BD2s%2FotleltQ%3D%3D
-
Grunberg SM. Antiemetic activity of corticosteroids in patients receiving cancer chemotherapy: Dosing, efficacy, and tolerability analysis. Ann Oncol. 2007;18:233-40.
-
(2007)
Ann Oncol
, vol.18
, pp. 233-240
-
-
Grunberg, S.M.1
-
39
-
-
0032938938
-
Role of dexamethasone dosage in combination with 5-HT3 antagonists for prophylaxis of acute chemotherapy-induced nausea and vomiting
-
10027342 10.1038/sj.bjc.6690100
-
Münstedt K, Müller H, Blauth-Eckmeyer E, et al. Role of dexamethasone dosage in combination with 5-HT3 antagonists for prophylaxis of acute chemotherapy-induced nausea and vomiting. Br J Cancer. 1999;79(3-4):637-9.
-
(1999)
Br J Cancer
, vol.79
, Issue.3-4
, pp. 637-639
-
-
Münstedt, K.1
Müller, H.2
Blauth-Eckmeyer, E.3
-
40
-
-
23444449690
-
Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: Analysis of combined data from two Phase III randomized clinical trials
-
15973669 10.1002/cncr.21222 1:CAS:528:DC%2BD2MXhtVSltr3P
-
Gralla RJ, de Wit R, Herrstedt J, et al. Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III randomized clinical trials. Cancer. 2005;104(4):864-8.
-
(2005)
Cancer
, vol.104
, Issue.4
, pp. 864-868
-
-
Gralla, R.J.1
De Wit, R.2
Herrstedt, J.3
-
41
-
-
79955017477
-
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: Randomized, double-blind study protocol-EASE
-
21383291 10.1200/JCO.2010.31.7859 1:CAS:528:DC%2BC3MXmt1Glsbc%3D
-
Grunberg S, Chua D, Maru A, et al. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol-EASE. J Clin Oncol. 2011;29(11):1495-501.
-
(2011)
J Clin Oncol
, vol.29
, Issue.11
, pp. 1495-1501
-
-
Grunberg, S.1
Chua, D.2
Maru, A.3
-
42
-
-
46749132406
-
Casopitant, a neurokinin-1 receptor antagonist with anti-emetic and anti-nausea activities
-
18600583 1:CAS:528:DC%2BD1cXpt1ajtb0%3D
-
Navari RM. Casopitant, a neurokinin-1 receptor antagonist with anti-emetic and anti-nausea activities. Curr Opin Investig Drugs. 2008;9(7):774-85.
-
(2008)
Curr Opin Investig Drugs
, vol.9
, Issue.7
, pp. 774-785
-
-
Navari, R.M.1
-
43
-
-
77954319603
-
Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: Results of the Perugia consensus conference
-
20555089 10.1093/annonc/mdq194
-
Roila F, Herrstedt J, Aapro M. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol. 2010;21(l5):v232-43.
-
(2010)
Ann Oncol
, vol.21
, Issue.L5
-
-
Roila, F.1
Herrstedt, J.2
Aapro, M.3
|